WO2006068826A3 - 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors - Google Patents

2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors Download PDF

Info

Publication number
WO2006068826A3
WO2006068826A3 PCT/US2005/044166 US2005044166W WO2006068826A3 WO 2006068826 A3 WO2006068826 A3 WO 2006068826A3 US 2005044166 W US2005044166 W US 2005044166W WO 2006068826 A3 WO2006068826 A3 WO 2006068826A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidinyl
pyrazolopyridine
kinase inhibitors
erbb kinase
erbb
Prior art date
Application number
PCT/US2005/044166
Other languages
French (fr)
Other versions
WO2006068826A2 (en
Inventor
Scott Howard Dickerson
Holly Kathleen Emerson
Philip Anthony Harris
Robert Dale Hubbard
Douglas Mccord Sammond
Kirk Lawrence Stevens
David Edward Uehling
Alex Gregory Waterson
Joseph W Wilson
Original Assignee
Scott Howard Dickerson
Holly Kathleen Emerson
Philip Anthony Harris
Robert Dale Hubbard
Douglas Mccord Sammond
Smithkline Beecham Corp
Kirk Lawrence Stevens
David Edward Uehling
Alex Gregory Waterson
Joseph W Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US63792804P priority Critical
Priority to US60/637,928 priority
Priority to US70907905P priority
Priority to US60/709,079 priority
Application filed by Scott Howard Dickerson, Holly Kathleen Emerson, Philip Anthony Harris, Robert Dale Hubbard, Douglas Mccord Sammond, Smithkline Beecham Corp, Kirk Lawrence Stevens, David Edward Uehling, Alex Gregory Waterson, Joseph W Wilson filed Critical Scott Howard Dickerson
Priority claimed from US11/721,504 external-priority patent/US7812022B2/en
Publication of WO2006068826A2 publication Critical patent/WO2006068826A2/en
Publication of WO2006068826A3 publication Critical patent/WO2006068826A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
PCT/US2005/044166 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors WO2006068826A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US63792804P true 2004-12-21 2004-12-21
US60/637,928 2004-12-21
US70907905P true 2005-08-17 2005-08-17
US60/709,079 2005-08-17

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/721,504 US7812022B2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
AT05853157T AT430747T (en) 2004-12-21 2005-12-06 2-pyrimidinyl-pyrazolopyridine erbB kinase inhibitors
EP20050853157 EP1828185B1 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
DE200560014382 DE602005014382D1 (en) 2004-12-21 2005-12-06 2-pyrimidinyl-pyrazolopyridine erbB kinase inhibitors
JP2007546747A JP5132319B2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitor

Publications (2)

Publication Number Publication Date
WO2006068826A2 WO2006068826A2 (en) 2006-06-29
WO2006068826A3 true WO2006068826A3 (en) 2006-10-05

Family

ID=36588699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044166 WO2006068826A2 (en) 2004-12-21 2005-12-06 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors

Country Status (6)

Country Link
EP (1) EP1828185B1 (en)
JP (1) JP5132319B2 (en)
AT (1) AT430747T (en)
DE (1) DE602005014382D1 (en)
ES (1) ES2325035T3 (en)
WO (1) WO2006068826A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812022B2 (en) 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
NZ556761A (en) * 2005-01-25 2011-04-29 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
ES2421450T3 (en) * 2005-12-05 2013-09-02 Glaxosmithkline Llc 2-pyrimidinyl-pyrazolopyridines ErbB kinase inhibitor
US8258129B2 (en) * 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008129070A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
WO2009103032A1 (en) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
JP2012528175A (en) * 2009-05-27 2012-11-12 アボット・ラボラトリーズAbbott Laboratories Pyrimidine inhibitors of the kinase activity
WO2010138575A1 (en) * 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
WO2011053476A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
UY33213A (en) 2010-02-18 2011-09-30 Almirall Sa Pyrazole derivatives as inhibitors of Jak
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
AR080375A1 (en) 2010-03-05 2012-04-04 Sanofi Aventis Process for the preparation of 2- (cicloheximetil) -N- {2 - [(2S) -1-methylpyrrolidin-2-yl] ethyl} -1,2,3,4-7-sulfonamide tetrahidroisoquinolina-
EP2402336A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EA201391626A1 (en) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. The compounds to inhibit cell proliferation in egfr-stimulated cancers
CN104109151B (en) * 2011-07-27 2017-04-12 阿斯利康(瑞典)有限公司 N- (2- {2- dimethylaminoethyl - methylamino} -4-methoxy-5 - {[4- (1-methyl-indol-3-yl) pyrimidin-2-yl] amino} phenyl) prop-2-enamide mesylate polymorph
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
ME03042B (en) * 2012-11-19 2018-10-20 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053942A1 (en) * 2000-08-22 2004-03-18 Alberti Michael John Fused pyrazole derivatives bieng protein kinase inhibitors
US6727256B1 (en) * 1998-01-12 2004-04-27 Smithkline Beecham Corporation Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727256B1 (en) * 1998-01-12 2004-04-27 Smithkline Beecham Corporation Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US20040053942A1 (en) * 2000-08-22 2004-03-18 Alberti Michael John Fused pyrazole derivatives bieng protein kinase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Also Published As

Publication number Publication date
DE602005014382D1 (en) 2009-06-18
JP5132319B2 (en) 2013-01-30
EP1828185B1 (en) 2009-05-06
AT430747T (en) 2009-05-15
ES2325035T3 (en) 2009-08-24
WO2006068826A2 (en) 2006-06-29
JP2008524220A (en) 2008-07-10
EP1828185A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TWI255185B (en) Novel compounds
AP2332A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
MXPA06015192A (en) Pyrrolotriazine kinase inhibitors.
MX2008012096A (en) C-met protein kinase inhibitors for the treatment of proliferative disorders.
WO2005123672A3 (en) Kinase inhibitors
ZA200501851B (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors.
MX2008005717A (en) Aminopyrimidines useful as kinase inhibitors.
TW200720257A (en) Pyrimidine compounds and methods of use
CA2565411A1 (en) Compounds and methods for inhibiting mitotic progression
EA027573B1 (en) Bicyclic heteroaryl compounds
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
TW200813020A (en) Substituted 3-amino-pyrrolidino-4-lactams
AU8765401A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation andpharmaceutical compositions comprising them
CA2430363A1 (en) Compounds and their uses
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
MX2007009429A (en) Pyrrolopyrimidines useful as inhibitors of protein kinase.
MX2008007049A (en) Inhibitors of c-met and uses thereof.
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2006069363A3 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
CA2523831A1 (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11721504

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005853157

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007546747

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005853157

Country of ref document: EP